Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease:
- PDF / 499,914 Bytes
- 17 Pages / 595.276 x 790.866 pts Page_size
- 98 Downloads / 256 Views
ORIGINAL RESEARCH
Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis Alicia Gayle . Nils Schoof . Margarida Alves . Deborah Clarke . Christina Raabe . Prithwiraj Das . Francesco Del Galdo . Toby M. Maher Received: February 7, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) places a substantial burden on patients and healthcare systems. The objectives of this study were to describe clinical characteristics and assess healthcare resource utilization and costs of patients with SSc-ILD in England, compared with patients with nonpulmonary organ involvement related to SSc (SSc-OOI). Digital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare.12046224. Electronic supplementary material The online version of this article (https://doi.org/10.1007/s12325020-01330-0) contains supplementary material, which is available to authorized users. A. Gayle D. Clarke P. Das Boehringer Ingelheim Ltd, Bracknell, UK N. Schoof M. Alves C. Raabe Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany F. Del Galdo University of Leeds, Leeds, UK T. M. Maher Fibrosis Research Group, National Heart and Lung Institute, Imperial College London, London, UK T. M. Maher (&) Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK e-mail: [email protected]
Methods: This population-based retrospective study used data from the Clinical Practice Research Datalink linked to Hospital Episode Statistics. Data were extracted from medical records dated January 1, 2005 to March 31, 2016. Patients with SSc were identified and placed in subgroups based on organ involvement: SSc-ILD, SSc-OOI, and both (SSc-ILDOOI). Patients with SSc-ILD-OOI were included in both the SSc-ILD and SSc-OOI subgroups. Allcause healthcare costs, excluding medication costs, were calculated to 2016 British pounds sterling (£). Results: This study included 675 patients with SSc: 174 (26%) had neither ILD nor other organ involvement (OOI); 127 (19%) had SSc-ILD; 477 (71%) had SSc-OOI; 103 (15%) had SSc-ILDOOI. Age-weighted median [interquartile range (IQR)] annual healthcare costs per patient were: £1496 (£664–£2817) in SSc only; £6375 (£3451– £15,041) in SSc-ILD; £4084 (£1454–£10,105) in SSc-OOI; £6632 (£4023–£17,009) in SSc-ILDOOI. In multivariate analysis, older age at diagnosis, diagnosis of anemia, and number of comorbid diseases were associated with higher yearly healthcare costs. Conclusion: The annual healthcare cost for patients with SSc-ILD is substantial, and higher than that of patients with SSc-OOI or SSc only. These results quantify the economic burden of SSc-ILD in a real-world setting, and highlight the need for treatment of this disease.
Adv Ther
PLAIN LANGUAGE SUMMARY
INTRODUCTION
SSc is a rare disease that causes fibrosis, or thickening, of the skin. In some patients, SSc can also affect the lungs (‘SSc-ILD’) or other org
Data Loading...
